Table of Contents
- Trial overview
- Who these trials study
- Trial designs and phases
- Main outcomes being measured
- Special patient groups
- What the trials compare
- Key terms from the studies
Trial overview
The clinical trials for Amiodarone Hydrochloride focus on heart rhythm problems in different patient groups.[1][2] The studies look at whether it helps restore or maintain sinus rhythm, which means a normal heartbeat, and whether it can improve other important outcomes such as safety and survival.[1][3]
Across the trial set, the main conditions include atrial fibrillation, frequent premature ventricular complexes, electrical storm, and out-of-hospital cardiac arrest with a shockable rhythm.[1][4][5] One study also examines how the drug is handled in the body in critically ill patients, using blood and other samples.[6]
Who these trials study
The target populations are varied and include people with paroxysmal atrial fibrillation in the emergency department, patients with persistent atrial fibrillation, and critically ill patients with new-onset atrial fibrillation.[1][2][6] Other studies include people with coronary disease without residual ischemia, people with hypertrophic cardiomyopathy, and people who had an acute ischemic stroke together with atrial fibrillation.[1][7][8]
One trial focuses on asymptomatic patients with frequent PVCs and normal left ventricular ejection fraction, meaning they do not have symptoms but do have many extra heartbeats and normal pumping function.[4] Another study includes patients after out-of-hospital cardiac arrest with an initial shockable rhythm, which means the heart rhythm could be treated with a shock at first contact.[5]
Trial designs and phases
Most of the listed studies are Phase 3 trials, which usually means the treatment is being tested in larger groups to learn more about benefit and safety in real patients.[1][2][3] One study is listed as Low Intervention, which means it uses a less intensive research approach than a standard drug trial.[4]
The trials are mostly interventional, meaning the study team gives a treatment plan and then measures results.[1][2] The statuses include Completed, Authorised, and Withdrawn, so the set includes finished studies, active or approved studies, and one study that did not continue.[1][4][5]
Main outcomes being measured
The main outcomes vary by study but stay centered on heart rhythm control and patient safety.[1][2] Some trials measure the first recurrence of atrial fibrillation, while others measure the chance of successful cardioversion to sinus rhythm within hours after treatment.[1][2]
Safety outcomes include events such as premature ventricular complexes, non-sustained ventricular tachycardia, supraventricular tachycardia, bradycardia, and low systolic blood pressure.[1] Other trials measure broader clinical outcomes such as death, stroke, transient ischemic attack, hospital admission, worsening heart failure, and acute coronary syndrome.[7][8][5]
One study measures pharmacokinetics, which means the amount of Amiodarone Hydrochloride and its active metabolite, N-desethylamiodarone, found in blood, bronchoalveolar lavage, and exhaled breath condensate.[6] This helps researchers compare intravenous and enteral use in critically ill patients.[6]
Special patient groups
Several trials focus on groups with higher clinical complexity.[3][7] For example, patients with hypertrophic cardiomyopathy and atrial fibrillation are studied because the trial aims to compare drug-based strategies with early ablation to prevent recurrence.[7]
Other special groups include critically ill mechanically ventilated patients with new-onset atrial fibrillation and patients after out-of-hospital cardiac arrest with a shockable rhythm.[6][5] These studies ask whether Amiodarone Hydrochloride can help in urgent or intensive care settings where heart rhythm problems are especially serious.[5][6]
What the trials compare
Some studies compare Amiodarone Hydrochloride with another antiarrhythmic drug, such as flecainide, to see which treatment works better for converting atrial fibrillation to sinus rhythm.[1] Others compare two Amiodarone Hydrochloride regimens, such as standard and reduced doses, or different preparation schedules before electrical cardioversion.[2][3]
In the hypertrophic cardiomyopathy study, one of the compared strategies is Amiodarone Hydrochloride, while other strategies use beta-blockers, sotalol, or early ablation.[7] In the stroke study, Amiodarone Hydrochloride is part of an early rhythm-control approach compared with usual care alone.[8]
The PARACA study tests whether prophylactic use of Amiodarone Hydrochloride for 72 hours after out-of-hospital cardiac arrest can lower death and serious in-hospital ventricular arrhythmias.[5] This shows that the research is not only about rhythm conversion, but also about preventing dangerous repeat events in very ill patients.[5]
Key terms from the studies
Electrical cardioversion means a planned electrical treatment used to reset the heart rhythm, and some trials measure rhythm outcomes after this procedure.[2] ECG, or electrocardiogram, is a heart tracing used to confirm whether atrial fibrillation has come back.[2]
LV dysfunction means weak pumping of the left ventricle, the main pumping chamber of the heart, and one study uses this as a long-term outcome in patients with frequent PVCs.[4] TEE or TTE are imaging tests used in some studies when measuring heart function or rhythm-related changes, and cMRI is cardiac magnetic resonance imaging.[4]
ATP, internal DC shock, and external DC shock are treatments used to stop ventricular arrhythmias in the electrical storm study, and the trial measures whether these events are fully suppressed after treatment.[5] Bronchoalveolar lavage is a sample taken from the lungs, and exhaled breath condensate is a collected breath sample used in the pharmacokinetic study.[6]
